An observational study in Systemic Lupus Erythematous (SLE), sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica. Not yet recruiting at 16 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Lupus Erythematosus, Systemic with a site in Italy — 23 open to participants now, 41 under way, 18 of them phase 3. Lupus Erythematosus, Systemic · Italy.
Among the 81 studies in Lupus Erythematosus, Systemic with a site in Italy, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2025, is one of 13 observational ones, reaches primary completion later than 13 of the 40 other live ones, and was the 69th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →23 of the 81 studies in Lupus Erythematosus, Systemic with a site in Italy are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in Italy, Australia, Brazil and 3 more countries
Ages 18–75
AstraZeneca · Sites in Italy, United States, Argentina and 32 more countries
Ages 5–80
Hoffmann-La Roche · Sites in Italy, Argentina, Brazil and 3 more countries
Ages 18+
AstraZeneca · Sites in Italy, United States, Canada and 6 more countries
Ages 18–70
EMD Serono Research & Development Institute, Inc. · Sites in Italy, United States, Australia and 17 more countries
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 36 · Phase 4 2
First in 2004; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 151 across 281 observational studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 296 across the 68 interventional studies, 300 across the 13 observational. Of the 36 that completed or were terminated, 29 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 81 have an industry lead sponsor. The 10 most frequent:
Società Italiana di Allergologia, Asma e Immunologia Clinica is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Società Italiana di Allergologia, Asma e Immunologia Clinica has 1 study filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
7 of the studies in Lupus Erythematosus, Systemic with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05624749Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | 2027-04-12 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07175610Società Italiana di Allergologia, Asma e Immunologia ClinicaLUpus Eritematoso Sistemico NETwork and Registry | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Lupus Erythematosus, Systemic with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LUNET Registry is intended to serve as a comprehensive primary data source, capturing real-world longitudinal clinical information, and the heterogeneity of patient presentations that are often underrepresented in traditional clinical trials. Ultimately, the LUNET Registry will help to optimize SLE management in routine clinical practice by enabling the compilation of real-world evidence to inform clinical decision-making and health policy. Patients will be enrolled by secondary and tertiary care centres for SLE across Italy in a real-world clinical set-up.
The LUNET's specific objectives are as follows:
Patients with SLE according to the SLICC 2012 and/or ACR/EULAR 2019 classification criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Remission
Number of patients who achieved complete clinical remission or low disease activity
Time frame: Every year to ten year
Disease activity
Changes in disease activity (SLEDAI-2k)
Time frame: Every year to ten year
Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.
Of 90 non-industry observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 212. This study's planned 15 months is below that.
Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 30 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
Società Italiana di Allergologia, Asma e Immunologia Clinica